The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
miR-122 is a Unique Molecule with Great Potential in Diagnosis, Prognosis of Liver Disease, and Therapy Both as miRNA Mimic and Antimir
Open accessAbstract
miR-122, a completely conserved liver-specific miRNA in vertebrates, is essential for the maintenance of liver homeostasis. This 22 nucleotide RNA regulates diverse functions such as cholesterol, glucose and iron homeostasis, lipid metabolism and infection of hepatitis C virus (HCV) and of the parasitic protozoa, Leishmania donovani. It is the first miRNA that underwent successful clinical trials in HCV infected patients. In contrast, miR-122 expression is reduced in nonalcoholic steatohepatitis (NASH) patients, and in a subset of hepatocellular carcinoma (HCC) patients including hepatitis B virus (HBV) positive patients with highly invasive and metastatic cancer. Studies in mice genetically depleted of miR-122 have highlighted its critical role in liver biology. These mice progressively develop steatohepatitis, fibrosis and hepatocellular cancer, establishing it as a bona fide tumor suppressor. Additionally, delivery of miR-122 using a viral vector or liposomal nanoparticles resulted in liver tumor suppression in animal models. These results suggest miR-122 supplementation might be beneficial in NASH or HBV positive HCC patients. Furthermore, circulating miR-122 has emerged as a sensitive biomarker for liver injury. The ability of miR-122 to promote differentiation of embryonic and adult stem cells to hepatocyte-like cells in vitro suggests its potential role in driving the hepatic differentiation program. In this review, we will discuss the role of miR-122 in liver physiology and the deleterious consequences of its loss of function, its role as a sensitive biomarker for liver injury and therapeutic target. Development of novel technologies for targeted delivery of miR-122 to tumor cells and for direct monitoring of miR-122 in biological fluids is urgently needed for translating the basic research to the bedside. This review focuses on miR-122, the most abundant hepatic miRNA, in the context of liver health and diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.040 · Cited by 3,626
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589 · cited 3×
“However, decreases in both potentially atherogenic LDL-cholesterol and cardio-protective HDLcholesterol in rodents [16] and primates [35] suggest that implementing anti-miR-122 therapy may not be optimal for cardiovascular risk management in human patients.”
BackgroundMethodMicroRNA Expression in Zebrafish Embryonic Development
Wienholds, E., Kloosterman, W. P., Miska, E., Alvarez-Saavedra, E., Berezikov, E., de Bruijn, E., Horvitz, H. R., Kauppinen, S., & Plasterk, R. H. A. (2005) · Science · doi:10.1126/science.1114519 · Cited by 1,551 · cited 1×
“In situ hybridization in zebrafish detected miR-122 expression only in the liver [4] confirming it as a liver-specific miRNA.”
BackgroundTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Engineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761
Cited by
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Ezzat, A., Wu, M., Li, X.-L., & Kwoh, C.-K. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby002 · Cited by 314
Recent advances in hepatocellular carcinoma therapy
Dutta, R., & Mahato, R. I. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.010 · Cited by 280
Luna, J. M., Barajas, J. M., Teng, K.-Y., Sun, H.-L., Moore, M. J., Rice, C. M., Darnell, R. B., & Ghoshal, K. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.025 · Cited by 80
Self-citationmiR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2
Li, X.-N., Yang, H., & Yang, T. (2020) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504019x15615433287579 · Cited by 34
Retracted
Metadata
- Authors
- Thakral, S., & Ghoshal, K.
- Venue
- Current Gene Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2015-03-09
- Volume
- 15
- Issue
- 2
- Pages
- 142-150
- ISSN
- 1566-5232 (ISSN-L)
- OpenAlex
- W2057650091
- Cited by
- 235
- References
- 9
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: miR-122 is a Unique Molecule with Great Potential in Diagnosis, Prognosis of Liver Disease, and Therapy Both as miRNA Mimic and Antimir. https://app.cochat.ai/papers/10.2174/1566523214666141224095610
- The paper
- Thakral, S., & Ghoshal, K. (2015). miR-122 is a Unique Molecule with Great Potential in Diagnosis, Prognosis of Liver Disease, and Therapy Both as miRNA Mimic and Antimir. Current Gene Therapy. https://doi.org/10.2174/1566523214666141224095610
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.